EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Predictors of Target Lesion Failure in Patients With In-Stent Restenosis: Insights From the AGENT IDE Trial

J Dawn Abbott iD, Nicholas Kassis, Azeem Latib iD, Richard A Shlofmitz iD, Jeffrey W Moses iD, William B Bachinsky, Suhail Dohad iD, Steven G Rudick, Robert C Stoler iD, Brian K Jefferson iD, William J Nicholson iD, John D Altman und 5 weitere

Circulation: Cardiovascular Interventions · 2026-10 · 19 (10)

DOI: 10.1161/circinterventions.125.016289 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2026-10. Verfasst von J Dawn Abbott und 16 weiteren Autor:innen. Beteiligte Einrichtung: Brown University Health Cardiovascular Institute, Providence, RI (J.D. Abbott). Hauptthemen laut MEDLINE: Coronary Restenosis, Paclitaxel, Angioplasty, Balloon, Coronary, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Predictors of target lesion failure (TLF) after percutaneous coronary intervention with drug-coated balloon therapy in patients with in-stent restenosis, as opposed to de novo disease, are limited. This post hoc analysis of the AGENT IDE trial (Agent Paclitaxel-Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis) aimed to identify predictors of TLF in patients with in-stent restenosis treated with a paclitaxel-coated balloon. METHODS: Of the 600 patients with in-stent restenosis in the AGENT IDE trial, 406 were randomized to treatment with the paclitaxel-coated balloon. Among this cohort, demographic, clinical, and core laboratory angiographic data were assessed using a Cox proportional hazards model to identify independent predictors of TLF, defined as the composite occurrence of ischemia-driven target lesion revascularization, target vessel-related myocardial infarction, or cardiac death, at 2-year follow-up. RESULTS: Independent risk factors for 2-year TLF, which occurred in 106 (27.0%) of patients, included multiple stent layers (hazard ratio, 1.80 [95% CI, 1.23–2.65]), White race (hazard ratio, 1.71 [95% CI, 1.03–2.85]), and postlesion preparation in-lesion % diameter stenosis (per 10% increment; hazard ratio, 1.16 [95% CI, 1.03–1.31]). The presence of the target lesion in the left anterior descending artery was associated with a reduced risk of 2-year TLF (hazard ratio, 0.56 [95% CI, 0.36–0.87]). CONCLUSIONS: Our findings highlight the variable risk of in-stent restenosis governed by relatively few patient and lesion factors and underscore the significance of optimal lesion preparation before drug-coated balloon therapy as a potentially modifiable factor. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04647253.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary RestenosisPaclitaxelAngioplasty, Balloon, CoronaryPercutaneous Coronary InterventionCardiovascular AgentsStentsCardiac CathetersCoated Materials, BiocompatibleDrug-Eluting StentsHumansFemaleMaleRisk FactorsAgedMiddle AgedTime FactorsTreatment FailureCoronary AngiographyRisk Assessment

Stichwörter der Autor:innen

angioplastyarteriescathetersrisk factorsstents

Substanzen

PaclitaxelCardiovascular AgentsCoated Materials, Biocompatible

Autor:innen und Institutionen

  • Brown University Health Cardiovascular Institute, Providence, RI (J.D. Abbott).
  • Warren Alpert Medical School, Department of Medicine, Providence, RI (N.K.).
  • Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (A.L.).
  • St Francis Heart Center at Good Samaritan Hospital, Roslyn, NY (R.A.S., J.W.M.).
  • Columbia University Irving Medical Center/New York-Presbyterian Hospital and the Cardiovascular Research Foundation (J.W.M., A.J.K.).
  • University of Pittsburgh Medical Center, Central PA, Harrisburg (W.B.B.).

ORCID-Profile: J Dawn Abbott, Azeem Latib, Richard A Shlofmitz, Jeffrey W Moses, Suhail Dohad, Robert C Stoler, Brian K Jefferson, William J Nicholson, Amar Krishnaswamy, Robert W Yeh, Ajay J Kirtane

Zitieren

APA

Abbott, J. D., Kassis, N., Latib, A., Shlofmitz, R. A., Moses, J. W., Bachinsky, W. B., Dohad, S., Rudick, S. G., Stoler, R. C., Jefferson, B. K., Nicholson, W. J., Altman, J. D., Bateman, C. T., Krishnaswamy, A., Cavalcante, R., Yeh, R. W., & Kirtane, A. J. (2026). Predictors of Target Lesion Failure in Patients With In-Stent Restenosis: Insights From the AGENT IDE Trial. Circulation: Cardiovascular Interventions, 19(10). https://doi.org/10.1161/circinterventions.125.016289

Vancouver

Abbott JD, Kassis N, Latib A, Shlofmitz RA, Moses JW, Bachinsky WB, et al. Predictors of Target Lesion Failure in Patients With In-Stent Restenosis: Insights From the AGENT IDE Trial. Circulation: Cardiovascular Interventions. 2026;19(10). doi:10.1161/circinterventions.125.016289

BibTeX
@article{Abbott2026,
  author = {Abbott, J Dawn and Kassis, Nicholas and Latib, Azeem and Shlofmitz, Richard A and Moses, Jeffrey W and Bachinsky, William B and Dohad, Suhail and Rudick, Steven G and Stoler, Robert C and Jefferson, Brian K and Nicholson, William J and Altman, John D and Bateman, Cinthia T and Krishnaswamy, Amar and Cavalcante, Rafael and Yeh, Robert W and Kirtane, Ajay J},
  title = {Predictors of Target Lesion Failure in Patients With In-Stent Restenosis: Insights From the AGENT IDE Trial},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2026},
  volume = {19},
  number = {10},
  doi = {10.1161/circinterventions.125.016289}
}
Kostenlos starten →